Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,099 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Healthy Control Subjects Clear all

Conditions: Pharmacokinetics
Interventions: Natrunix, Placebo; Biological
Lead sponsor: XBiotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Influenza
Interventions: Peramivir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: PSD502; Drug
Lead sponsor: Plethora Solutions Ltd; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Healthy
Interventions: Diacerein 1% ointment; Drug
Lead sponsor: Castle Creek Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Renal Disease, End Stage
Interventions: Amisulpride IV, Amisulpride Oral Tablet; Drug
Lead sponsor: Acacia Pharma Ltd; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Miami Lakes, Florida

Conditions: Mydriasis, Dilation
Interventions: Phentolamine Ophthalmic Solution 0.75%, Phentolamine Ophthalmic Solution Vehicle (Placebo); Drug · Other
Lead sponsor: Opus Genetics, Inc; Industry
Eligibility: 12 Years and older
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 12
States / cities: Newport Beach, California • San Diego, California • Longwood, Florida + 9 more

Conditions: Type 2 Diabetes Mellitus
Interventions: DS-1150b, Placebo; Drug · Other
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Healthy Participants
Interventions: AZD6234, Placebo, Acetaminophen; Drug · Combination Product
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Hepatitis C
Interventions: TD-6450, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Subjects
Interventions: GSK1349572; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Healthy
Interventions: Intra-epidermal stimulation electrode; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 21 Years to 60 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Pain, Acute
Interventions: TRV130 1.5 mg, TRV130 3 mg, TRV130 4.5 mg, Morphine 10 mg, Placebo; Drug
Lead sponsor: Trevena Inc.; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy
Interventions: HM10460A or placebo or Neulasta; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 20 Years to 45 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: California City, California

Conditions: Systemic Lupus Erythematosus
Interventions: KPG-818; Drug
Lead sponsor: Kangpu Biopharmaceuticals, Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Glendale, California

Conditions: Obese, Overweight, Healthy
Interventions: LB64640, Placebo; Drug
Lead sponsor: LG Chem; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 112 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: TQT Study
Interventions: Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) + Placebo, Moxifloxacin 400mg, Placebo for Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr), Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr); Drug · Other
Lead sponsor: Spero Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Healthy Volunteer
Interventions: Placebo, RO4995819; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 65 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Healthy
Interventions: diacerein 1% ointment; Drug
Lead sponsor: Castle Creek Pharmaceuticals, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Dry Skin
Interventions: AmLactin® Rapid Relief; Other
Lead sponsor: Sandoz; Industry
Eligibility: 50 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Parkinson's Disease
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: Not listed
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Subjects, Osteoarthritis
Interventions: AGG-523; Drug
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 40 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: PF-06291874, placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Peripheral Arterial Disease, Diabetes Mellitus
Interventions: SPECT/CT imaging following revascularization procedures, SPECT/CT imaging; Device
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy Subjects
Interventions: MGD010, Placebo, Hepatitis A vaccine; Drug · Biological
Lead sponsor: MacroGenics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy Volunteers

Safety and Dose Study of Peramivir for Influenza Treatment

Phase I Study of PSD502 (Lidocaine Prilocaine Spray) Applied to the Glans Penis up to Three Times a Day for 21 Days in Healthy Male Volunteers

A 6-Week Study to Evaluate the Photoallergic Potential of Diacerein 1% Ointment in Healthy Volunteers

PK Study of IV and Oral Amisulpride in Subjects With Severe Renal Impairment

Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis

Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of DS-1150b in Healthy Subjects and Subjects With Type-2 Diabetes Mellitus

Assess the Safety, Tolerability, and Pharmacokinetics of AZD6234 Following Single Ascending Dose Administration to Healthy Subjects Who Are Overweight or Obese

TD-6450 SAD and MAD in Healthy Subjects

GSK1349572 First Time in Human Study

Intra-epidermal Stimulation (IES) of Small Nerve Fibers (A-delta Fibers)

Pharmacokinetics and Pharmacodynamics of TRV130, Morphine, and Placebo in Healthy Subjects

Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects

Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects

A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects

A Single-Dose, Randomized, Placebo- and Active-Control, Four-Way, Cross-Over Study for the Evaluation of the Effect of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) on the QT/QTc Intervals in Adult Healthy Subjects

A Study of RO4995819 in Healthy Elderly Volunteers

A 21 Day Irritation Study in Healthy Volunteers With Diacerein 1% Ointment

This Was a Clinical Study Investigating the Moisturization and Desquamation Effect of AmLactin® Rapid Relief Restoring Lotion + Ceramides on Dry Skin in Healthy Female Volunteers. AmLactin® Rapid Relief is an Over-the-counter Cosmetic

Effect of Stimulus Rate on Cognitive and Motor Activity in Young Subjects, Elderly Subjects, and Patients With Parkinson's Disease

Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy

Single Dose Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06291874 In Healthy Adult Subjects

SPECT/CT Imaging of Skeletal Muscle Perfusion

Phase 1 Study of MGD010 in Healthy Subjects